Role of fibrinogen in complement inhibition by streptococcal M protein. (original) (raw)

• Journal List
• Infect Immun
• v.60(12); 1992 Dec
• PMC258274

Infect Immun. 1992 Dec; 60(12): 5036–5041.

Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.

Abstract

M protein, the major virulence factor of group A streptococci, has antiopsonic activity in that it inhibits activation of the alternative complement pathway on the streptococcal surface. Two properties of M protein have been claimed to account for the inhibitory activity, namely, (i) its binding affinity for complement factor H, which is an inhibitor of alternative pathway activation, and (ii) its high binding affinity for fibrinogen. We have recently shown that fibrinogen, like M protein, inhibits alternative pathway activation by possessing binding affinity for factor H. Here we report that fibrinogen effectively competes with factor H for binding to M protein but retains its own binding affinity for factor H. The presence of fibrinogen did not significantly affect alternative pathway inhibition on the streptococcal surface.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

• BECKER CG. SELECTION OF GROUP A STREPTOCOCCI RICH IN M-PROTEIN FROM POPULATIONS POOR IN M-PROTEIN. Am J Pathol. 1964 Jan;44:51–60. [PMC free article] [PubMed] [Google Scholar]
• Chhatwal GS, Dutra IS, Blobel H. Fibrinogen binding inhibits the fixation of the third component of human complement on surface of groups A, B, C, and G streptococci. Microbiol Immunol. 1985;29(10):973–980. [PubMed] [Google Scholar]
• Fearon DT. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971–1975. [PMC free article] [PubMed] [Google Scholar]
• Fischetti VA, Jones KF, Manjula BN, Scott JR. Streptococcal M6 protein expressed in Escherichia coli. Localization, purification, and comparison with streptococcal-derived M protein. J Exp Med. 1984 Apr 1;159(4):1083–1095. [PMC free article] [PubMed] [Google Scholar]
• Götze O, Müller-Eberhard HJ. The C3-activator system: an alternate pathway of complement activation. J Exp Med. 1971 Sep 1;134(3 Pt 2):90s–108s. [PubMed] [Google Scholar]
• Hong K, Kinoshita T, Takeda J, Kozono H, Pramoonjago P, Kim YU, Inoue K. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein. Infect Immun. 1990 Aug;58(8):2535–2541. [PMC free article] [PubMed] [Google Scholar]
• Horstmann RD, Müller-Eberhard HJ. Demonstration of C3b receptor-like activity and of decay-accelerating factor-like activity on rabbit erythrocytes. Eur J Immunol. 1986 Sep;16(9):1069–1073. [PubMed] [Google Scholar]
• Horstmann RD, Pangburn MK, Müller-Eberhard HJ. Species specificity of recognition by the alternative pathway of complement. J Immunol. 1985 Feb;134(2):1101–1104. [PubMed] [Google Scholar]
• Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657–1661. [PMC free article] [PubMed] [Google Scholar]
• KANTOR FS. FIBRINOGEN PRECIPITATION BY STREPTOCOCCAL M PROTEIN. I. IDENTITY OF THE REACTANTS, AND STOICHIOMETRY OF THE REACTION. J Exp Med. 1965 May 1;121:849–859. [PMC free article] [PubMed] [Google Scholar]
• LANCEFIELD RC. Current knowledge of type-specific M antigens of group A streptococci. J Immunol. 1962 Sep;89:307–313. [PubMed] [Google Scholar]
• Lesavre PH, Müller-Eberhard HJ. Mechanism of action of factor D of the alternative complement pathway. J Exp Med. 1978 Dec 1;148(6):1498–1509. [PMC free article] [PubMed] [Google Scholar]
• Manjula BN, Schmidt ML, Fischetti VA. Unimpaired function of human phagocytes in the presence of phagocytosis-resistant group A streptococci. Infect Immun. 1985 Dec;50(3):610–613. [PMC free article] [PubMed] [Google Scholar]
• Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A. 1990 May;87(10):3982–3986. [PMC free article] [PubMed] [Google Scholar]
• Pangburn MK, Müller-Eberhard HJ. The alternative pathway of complement. Springer Semin Immunopathol. 1984;7(2-3):163–192. [PubMed] [Google Scholar]
• Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977 Jul 1;146(1):257–270. [PMC free article] [PubMed] [Google Scholar]
• Perkins SJ, Nealis AS, Sim RB. Oligomeric domain structure of human complement factor H by X-ray and neutron solution scattering. Biochemistry. 1991 Mar 19;30(11):2847–2857. [PubMed] [Google Scholar]
• Phillips GN, Jr, Flicker PF, Cohen C, Manjula BN, Fischetti VA. Streptococcal M protein: alpha-helical coiled-coil structure and arrangement on the cell surface. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4689–4693. [PMC free article] [PubMed] [Google Scholar]
• Pryzdial EL, Isenman DE. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact. J Biol Chem. 1987 Feb 5;262(4):1519–1525. [PubMed] [Google Scholar]
• Scott JR, Fischetti VA. Expression of streptococcal M protein in Escherichia coli. Science. 1983 Aug 19;221(4612):758–760. [PubMed] [Google Scholar]
• Tack BD, Prahl JW. Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry. 1976 Oct 5;15(20):4513–4521. [PubMed] [Google Scholar]
• Weis JJ, Law SK, Levine RP, Cleary PP. Resistance to phagocytosis by group A streptococci: failure of deposited complement opsonins to interact with cellular receptors. J Immunol. 1985 Jan;134(1):500–505. [PubMed] [Google Scholar]
• Whitnack E, Beachey EH. Antiopsonic activity of fibrinogen bound to M protein on the surface of group A streptococci. J Clin Invest. 1982 Apr;69(4):1042–1045. [PMC free article] [PubMed] [Google Scholar]
• Whitnack E, Beachey EH. Inhibition of complement-mediated opsonization and phagocytosis of Streptococcus pyogenes by D fragments of fibrinogen and fibrin bound to cell surface M protein. J Exp Med. 1985 Dec 1;162(6):1983–1997. [PMC free article] [PubMed] [Google Scholar]
• Whitnack E, Beachey EH. Biochemical and biological properties of the binding of human fibrinogen to M protein in group A streptococci. J Bacteriol. 1985 Oct;164(1):350–358. [PMC free article] [PubMed] [Google Scholar]
• Wright SD, Weitz JI, Huang AJ, Levin SM, Silverstein SC, Loike JD. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7734–7738. [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)